|1.||John, Gareth W: 2 articles (05/2003 - 05/2002)|
|2.||Perez, Michel: 1 article (05/2003)|
|3.||Le Grand, Bruno: 1 article (05/2003)|
|4.||Verscheure, Yvan: 1 article (05/2003)|
|5.||Colpaert, Francis C: 1 article (05/2003)|
|6.||Letienne, Robert: 1 article (05/2003)|
|7.||Mulder, Paul G H: 1 article (05/2002)|
|8.||van den Broek, Rémon W M: 1 article (05/2002)|
|9.||Avezaat, Cees J J: 1 article (05/2002)|
|10.||MaassenVanDenBrink, Antoinette: 1 article (05/2002)|
|1.||Migraine Disorders (Migraine)
03/01/2001 - "In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development . "
05/17/2002 - "The present results suggest that, like sumatriptan, donitriptan exhibits cranioselectivity and would be effective in aborting migraine attacks with a similar coronary side-effect profile as sumatriptan."
05/17/2002 - "We investigated the contractile effects of donitriptan and sumatriptan on human isolated blood vessels of relevance to therapeutic efficacy in migraine (middle meningeal artery) and coronary adverse events (coronary artery). "
03/01/2001 - "Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine . "
07/01/1999 - "F 11356 thus is a selective, high-potency agonist at 5-HT1B/1D receptors, which distinguishes itself from tryptamine and derivatives in exerting high intrinsic activity at these receptors in vascular and neuronal models relevant to migraine."
05/01/2001 - "Sumatriptan and donitriptan inhibited CGRP release as well as neurogenic inflammation. "
05/01/2001 - "The effects of classical and new anti-migraine drugs such as acetylsalicylic acid (ASA), sumatriptan and the new high efficacy 5-HT1B/1D agonist donitriptan (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) were evaluated in comparison with the established model of neurogenic inflammation in the meninges. "
05/01/2003 - "Since donitriptan also increased pVCO(2), an effect upon cerebral oxygen consumption and metabolism is suggested in addition to cranial vasoconstriction, which may be relevant to its headache-relieving effects."
05/01/2003 - "Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: further insights into its mechanism of action relevant to headache relief."
|2.||Serotonin 5-HT1 Receptor Agonists
|3.||Serotonin (5 Hydroxytryptamine)
|5.||Aspirin (Acetylsalicylic Acid)